New hope for rectal cancer: skipping radiation with chemo-immunotherapy
NCT ID NCT07127497
First seen Nov 21, 2025 · Last updated May 11, 2026 · Updated 22 times
Summary
This study tests whether a combination of chemotherapy and an immunotherapy drug (sintilimab) can effectively treat locally advanced rectal cancer without using radiation. About 50 patients with a specific genetic profile (pMMR/MSS) will receive this treatment before surgery. The goal is to see if this approach can shrink or eliminate tumors while helping patients avoid radiation side effects and possibly preserve organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022, China
Conditions
Explore the condition pages connected to this study.